Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
PROKDay performance
| PROK | |
|---|---|
| Price | 1.72 |
| Change Pct | -3.91 |
| Change Abs | -0.07 |
| Market Cap | 1.8 billion |
| Eps | -0.58 |
| Pe Ratio | -2.97 |
| Outstanding Shares | 1.1 billion |
| Volume | 913623 |
| Avg Volume | 990717 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | US |
| Announcement Earnings | 2023-11-14 13:00:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
CERE
RVMD
DICE
3 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
PROK
Company descriptions
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.